阿立哌唑与奥氮平对首发精神分裂症急性期疗效及对催乳素的影响

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (9): 1016-1020.

阿立哌唑与奥氮平对首发精神分裂症急性期疗效及对催乳素的影响

吴小立, 王继辉, 钟智勇, 韩自力

中山大学附属第三医院心理科,广州 510630,广东

收稿日期:2011-07-12 修回日期:2011-08-24 出版日期:2011-09-26 发布日期:2011-10-11
通讯作者: 韩自力,男,硕士,副主任医师,研究方向:精神病学与精神卫生。Tel: 020-85252190 E-mail: 13312883609@139.com
作者简介:吴小立,男,在职博士研究生,主治医师,研究方向:精神病学与精神卫生。Tel: 020-85253129 E-mail: wxlhzp2006@126.com
基金资助:
广东省科技计划基金项目:非典型抗精神病药物所致血脂异常的分子机制探讨(2009B080701080)

Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level

WU Xiao-li, WANG Ji-hui, ZHONG Zhi-yong, HAN Zi-li

Department of Psychology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong, China

Received:2011-07-12 Revised:2011-08-24 Online:2011-09-26 Published:2011-10-11

摘要/Abstract

摘要： 目的: 研究奥氮平和阿立哌唑对首发精神分裂症患者急性期疗效及对血中催乳素(PRL)水平的影响。方法: 65例首发精神分裂症患者分为奥氮平组42例[男21例,女21例;年龄(23.9±6.6)岁]和阿立哌唑组23例[男11例,女12例;年龄(23.7±7.2)岁]。分别给予奥氮平和阿立哌唑单药治疗4 周。在基线和4周末,分别用阳性症状与阴性症状量表(PANSS)、临床总体印象量表-疗效总评(CGI-I)评定疗效。放射免疫法测定血清催乳素水平。结果: 治疗4 周末,奥氮平组PANSS总分(59±13)较基线(103±15)明显下降;阿立哌唑组PANSS总分(60±18)较基线(101±13)明显下降,差异具有统计学意义(P＜0.01);治疗后,两组间CGI-I评分比较差异无统计学意义(P>0.05);治疗前后奥氮平组和阿立哌唑组之间PANSS量表阴性因子和一般精神病理因子分量表分的变化有统计学意义的差异(P＜0.01)。奥氮平组治疗后催乳素(418±362) uIu/mL 和基线(547±382) uIu/mL 比较虽有所下降,但差异无统计学意义(P >0.05);阿立哌唑组治疗后催乳素(123±114) uIu/mL较基线(351±299) uIu/mL下降,差异具有统计学意义(P <0.01)。结论: 阿立哌唑治疗首发精神分裂症患者急性期总体疗效和奥氮平相当。奥氮平对一般精神病理症状的改善优于阿立哌唑,阿立哌唑对阴性症状的改善优于奥氮平。阿立哌唑可能降低首发精神分裂症患者血催乳素水平。

关键词: 阿立哌唑, 奥氮平, 首发精神分裂症, 催乳素

Abstract: AIM: To study the efficacy on first-episode acute schizophrenia treated with aripiprazole and olanzapine and the effect on plasma prolactin level. METHODS: 65 inpatients with first-episode acute schizophrenia were divided into either olanzapine group[n=42, M21, F21; age(23.9±6.6)year] or aripiprazole group[(n=23, M11, F12; age(23.7±7.2)year] for 4 week treatment. The plasma prolactin level, the Positive and Negative Syndrome Scale(PANSS) and clinical global impression-global improvement(CGI-I) were measured before and after 4 week treatment. RESULTS: The score of PANSS (59±13)after therapy in olanzapine group was significantly lower than that before therapy (103±15) (P<0.01). The score of PANSS (60±18)after therapy in aripiprazole group was significantly lower than that before therapy (101±13) (P<0.01). After therapy, there was no significant difference(P>0.05) in the CGI-I score between the two groups.The difference of negative symptoms and general psychopathological sub-scale scores changing from base to end between the two groups was statistically significant(P<0.01). Compared with the prolactin baseline level (547±382) uIu/mL,the plasma prolactin level (418±362) uIu/mL in olanzapine group was significantly decreased after treatment,and there was no difference. Compared with the prolactin baseline level (351±299) uIu/mL, the plasma prolactin level (123±114) uIu/mL in aripiprazole group was significantly decreased after treatment,and there was significant difference(P<0.01). CONCLUSION: The therapeutic effects were similar in the aripiprazole and olanzapine group for first-episode acute schizophrenia.Olanzapine is better for the general psychopathological symptoms,and aripiprazole is better for the negative symptoms.Aripiprazole maybe decrease the plasma prolactin level of first-episode acute schizophrenia.

Key words: Aripiprazole, Olanzapine, First-episode schizophrenia, Prolactin

中图分类号:

R749.3

吴小立, 王继辉, 钟智勇, 韩自力. 阿立哌唑与奥氮平对首发精神分裂症急性期疗效及对催乳素的影响[J]. 中国临床药理学与治疗学, 2011, 16(9): 1016-1020.

WU Xiao-li, WANG Ji-hui, ZHONG Zhi-yong, HAN Zi-li. Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1016-1020.

参考文献

[1] Mailman RB,Murthy V.Third generation antipsychotic drugs: partial agonism or receptor functional selectivity [J]? Curr Pharm Des,2010,16(5): 488-501.
[2] 翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301.
[3] Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison[J].J Psychopharmacol,2011,25(6):744-754.
[4] Newcomer JW. Second-generation(atypical) antipsychotics and metabolic effects: a comprehensive literature review[J].CNS Drugs,2005,19(Suppl 1):1-93.
[5] Komossa K, Rummel-Kluge C, Schmid F,et al. Aripiprazole versus other atypical antipsychotics for schizophrenia[J]. Cochrane Database Syst Rev,2009,7(4):CD006569.
[6] 杜彪. 阿立哌唑与奥氮平治疗精神分裂症的系统评价[J].中国临床药理学杂志,2004,26(11):859-861.
[7] Halbreich U, Kinon BJ, Gilmore JA,et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects[J]. Psychoneuroendocrinol,2003, 28(Suppl 1):53-67.
[8] 徐乐平,纪菊英,施辉,等. 阿立哌唑治疗抗精神病药物所致高催乳素血症对照研究[J].中国行为医学科学,2006,15(8):718-720.
[9] Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study[J]. Schizophr Res,2009, 107(2/3):218-222.
[10] Cosi C,Carilla-Durand E,Assie MB,et al.Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release[J].Eur J Pharmacol,2006,535(1/2/3):135-144.
[11] Gorobets LN, Matrosova MI.Specialties of prolactin secretion and peripheral reproductive sex hormones in patients with of first episode of schizophrenia[J].Zh Nevrol Psikhiatr Im S S Korsakova, 2010,110(10):17-22.
[12] Akhondzadeh S, Rezaei F, Larijani B, et al.Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia[J].Schizophr Res,2006,84(2/3):405-410.

[1]	王校, 薛秋云, 黄玉蓉, 程成龙, 黄玉亭, 常俊, 尹群, 杜明松, 缪成贵. 禹州漏芦总甾酮对缺乳模型大鼠的催乳作用及分子机制研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 121-128.
[2]	杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.
[3]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[4]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[5]	陈连洲，李松华，蒲犇. 阿立哌唑联合草酸艾司西酞普兰对重度抑郁患者多巴胺、5-羟色胺和皮质醇的影响研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 446-450.
[6]	章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.
[7]	崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.
[8]	杨艳，夏泳，朱长江，陈艳波. 阿立哌唑对氨磺必利所致高泌乳素血症的影响研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 693-696.
[9]	曾慧, 屈刚, 肖兰, 田小娟, 易宏辉, 尹龙武, 孙红. 奥氮平对脂肪细胞UCP2和aP2表达的影响[J]. 中国临床药理学与治疗学, 2015, 20(2): 151-154.
[10]	倪平, 吕海龙, 国效峰, 张丽丽, 许林勇. 利培酮与奥氮平对精神分裂症急性期的疗效及临床影响因素的比较[J]. 中国临床药理学与治疗学, 2014, 19(2): 182-185.
[11]	俞凌燕, 楼洪刚, 阮邹荣, 江波, 陈金亮. 基于偏最小二乘模型的奥氮平血药达峰浓度与个体内在因素的相关性研究[J]. 中国临床药理学与治疗学, 2012, 17(9): 1022-1025.
[12]	张玉琦, 徐文炜, 程灶火, 吴越, 顾君, 汤莉, 季萍, 李桂林. 多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性对照研究[J]. 中国临床药理学与治疗学, 2012, 17(9): 1038-1041.
[13]	钟智勇, 张明, 王继辉, 吴小立. 利培酮口服液与奥氮平治疗脑器质性精神障碍疗效与安全性分析[J]. 中国临床药理学与治疗学, 2012, 17(9): 1047-1051.
[14]	杭荣华, 程万良, 王瑞权, 吴明飞. 奥氮平与利培酮治疗老年精神分裂症患者疗效及执行功能比较[J]. 中国临床药理学与治疗学, 2012, 17(7): 812-815.
[15]	许本健, 陈菊凤. 急性期精神分裂症转换帕利哌酮治疗的疗效及安全性[J]. 中国临床药理学与治疗学, 2012, 17(2): 215-219.